Genotoxic DNA double-strand breaks (DSBs) can be repaired by error-free homologous recombination (HR) or mutagenic non-homologous end-joining 1 . HR supresses tumorigenesis 1 , but is restricted to the S and G2 phases of the cell cycle when a sister chromatid is present 2 . Breast cancer type 1 susceptibility protein (BRCA1) promotes HR by antagonizing the antiresection factor TP53-binding protein 1(53BP1) (refs. 2-5 ), but it remains unknown how BRCA1 function is limited to the S and G2 phases. We show that BRCA1 recruitment requires recognition of histone H4 unmethylated at lysine 20 (H4K20me0), linking DSB repair pathway choice directly to sister chromatid availability. We identify the ankyrin repeat domain of BRCA1associated RING domain protein 1 (BARD1)-the obligate BRCA1 binding partner 3 -as a reader of H4K20me0 present on new histones in post-replicative chromatin 6 . BARD1 ankyrin repeat domain mutations disabling H4K20me0 recognition abrogate accumulation of BRCA1 at DSBs, causing aberrant build-up of 53BP1, and allowing anti-resection activity to prevail in S and G2. Consequently, BARD1 recognition of H4K20me0 is required for HR and resistance to poly (ADPribose) polymerase inhibitors. Collectively, this reveals that BRCA1-BARD1 monitors the replicative state of the genome to oppose 53BP1 function, routing only DSBs within sister chromatids to HR.
Genotoxic DNA double-strand breaks (DSBs) can be repaired by error-free homologous recombination (HR) or mutagenic non-homologous end-joining 1 . HR supresses tumorigenesis 1 , but is restricted to the S and G2 phases of the cell cycle when a sister chromatid is present 2 . Breast cancer type 1 susceptibility protein (BRCA1) promotes HR by antagonizing the antiresection factor TP53-binding protein 1(53BP1) (refs. [2] [3] [4] [5] ), but it remains unknown how BRCA1 function is limited to the S and G2 phases. We show that BRCA1 recruitment requires recognition of histone H4 unmethylated at lysine 20 (H4K20me0), linking DSB repair pathway choice directly to sister chromatid availability. We identify the ankyrin repeat domain of BRCA1associated RING domain protein 1 (BARD1)-the obligate BRCA1 binding partner 3 -as a reader of H4K20me0 present on new histones in post-replicative chromatin 6 . BARD1 ankyrin repeat domain mutations disabling H4K20me0 recognition abrogate accumulation of BRCA1 at DSBs, causing aberrant build-up of 53BP1, and allowing anti-resection activity to prevail in S and G2. Consequently, BARD1 recognition of H4K20me0 is required for HR and resistance to poly (ADPribose) polymerase inhibitors. Collectively, this reveals that BRCA1-BARD1 monitors the replicative state of the genome to oppose 53BP1 function, routing only DSBs within sister chromatids to HR.
Histone H4 lysine 20 (H4K20) methylation oscillates during the cell cycle, with major implications for chromosome replication, condensation and stability 7 . In the G1 phase, nucleosomes are fully methylated at H4K20, with >80% carrying H4K20 di-methylation (H4K20me2) (ref. 6 ). During S phase, new histone H4 unmethylated at K20 (H4K20me0) are incorporated on newly synthesized DNA and mixed in a 1:1 ratio with old nucleosomes methylated at H4K20. H4K20me0 thereby marks the post-replicative state of a genomic locus and thus the presence of a sister chromatid until G2/M 6 , when a surge of SET domain-containg protein 8 (SET8) methyltransferase activity catalyses mono-methylation of H4K20 (H4K20me1), which is subsequently converted to di-and trimethylation by suppressor of variegation 4-20 homologue 1/2 (SUV4-20h1/2) 6, 7 . The cell exploits this to regulate the recruitment of DNA repair factors. The TONSL (Tonsoku-like protein)-MMS22L (protein MMS22-like) homologous recombination (HR) 8 complex reads H4K20me0 via its ankyrin repeat domain (ARD) to direct its function in DNA repair protein RAD51 homologue 1 (RAD51) loading 9 to collapsed replication forks and DNA double-strand breaks (DSBs) in post-replicative chromatin 6 . Conversely, the nonhomologous end-joining (NHEJ)-promoting factor TP53-binding protein 1 (53BP1) recognizes H4K20me1/2 (ref. 10 ) present on old histones throughout the cell cycle 6 . 53BP1 accumulation at DSBs is reduced in post-replicative chromatin [11] [12] [13] , correlating with the replication-dependent dilution of H4K20me1/2 (refs. 6, 12, 13 ). However, H4K20me1/2 dilution cannot explain 53BP1 suppression and the shift to HR, as breast cancer type 1 susceptibility protein (BRCA1) is required to antagonize 53BP1 accumulation at DSBs in S/G2 (refs. 11, 12 ). DNA damage-induced ubiquitylation by RING finger proteins 8 (RNF8) and 168 (RNF168) is also required for both 53BP1 and BRCA1 recruitment 14 , but these signalling pathways are not cellcycle specific 14 . The crucial question of how BRCA1 specifically recognizes post-replicative chromatin thus remains a missing part in the puzzle to understand DSB repair pathway choice.
Because H4K20me0 directly marks sister chromatid availability, we set out to comprehensively explore its function. Using an unbiased quantitative proteomic strategy to identify proteins specifically recognizing nucleosomes carrying H4K20me0, we identified almost exclusively three post-replication DNA repair complexes; a BRCA1-BARD1 (BRCA1-associated RING domain protein 1)-containing complex involved in HR 3 ; the RAD18 (an E3 ubiquitin-protein ligase)-SLF1 (SMC5-SMC6 complex localization factor 1)-SLF2 complex implicated in interstrand cross-link repair 15 ; and TONSL-MMS22L, as expected 6 (Fig. 1a ). Consistent with previous work 7, 16 , leucine-rich repeat and WD repeat-containing protein 1 (LRWD1), origin recognition complex subunit 1 (ORC1), ORC2 and ORC3 were specifically enriched on nucleosomes carrying H4K20me2 ( Fig. 1a ). Intriguingly, BARD1 and SLF1 both contain ARDs with high similarity to the TONSL ARD that recognizes H4K20me0 (ref. 6 ) ( Fig. 1b and Supplementary Fig. 1 ), and the reported structure of the BARD1 ARD 17 revealed that the histone H4-binding interface 6 is structurally conserved (Fig. 1b ). BARD1 and SLF1 showed a clear . 1c ) and, importantly, mutation of three residues predicted to bind H4K20me0 (ARD 3A) based on TONSL homology abrogated nucleosome binding by SLF1 and BARD1 ( Fig. 1b,d) . These data identify two new H4K20me0 readers and argue for a general role of H4K20me0 in promoting post-replication DNA repair. In particular, recognition of H4K20me0 by BARD1 could provide a mechanism for BRCA1 recruitment to post-replicative 
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NATuRe Cell BIoloGy chromatin, and directly link induction of HR to sister chromatid availability. Here, we explore this hypothesis. As H4K20me0 marks post-replicative chromatin irrespective of DNA lesions 6 , BRCA1-BARD1 might bind post-replicative chromatin in unperturbed cells. Indeed, we found progressive accumulation of the BRCA1-BARD1 complex on chromatin during the S phase mirroring H4K20me0 incorporation 6 ( Fig. 2a and Supplementary  Fig. 2a ,b), and this was dependent on H4K20me0 recognition by the BARD1 ARD ( Fig. 2b and Supplementary Fig. 2c-e ). BARD1 localized to 5-ethynyl-2'-deoxyuridine (EdU) pulse-labelled replication foci in the early S phase, but co-localization decreased in the midand late S phase ( Fig. 2c ). With continuous EdU labelling of postreplicative DNA, BARD1 and EdU co-localization remained high throughout the S phase ( Fig. 2c) , consistent with the recruitment of BARD1 via H4K20me0 present at sites of ongoing replication, as well as in post-replicative chromatin 6 . Depletion of SET8, which is responsible for methylation of H4K20 in G2 and mitosis, increased H4K20me0 levels and augmented BRCA1-BARD1 binding to chromatin in G2 and G1 in a manner dependent on H4K20me0 recognition by the BARD1 ARD ( Fig. 2d and Supplementary Fig. 2f -h). SET8-depleted cells showed reduced NHEJ and elevated rates of HR and single-stranded DNA annealing 18 , but due to pleiotropic defects such as chromatin decompaction and DNA damage, this system was unsuitable for testing the role of H4K20me0 recognition in supporting BRCA1-BARD1-dependent HR. Taken together, our results establish ARD-dependent recognition of H4K20me0 as a mechanism for general pre-lesion recruitment of BRCA1-BARD1 to post-replicative chromatin, irrespective of DNA damage.
Next, we analysed the role of H4K20me0 binding by BARD1 ARD in DNA DSB repair. Wild-type BARD1 recruitment to ionizing irradiation-induced DSBs increased during the S phase and reached a maximum in the late S phase before dropping in G2/M ( Fig. 3a ), mirroring H4K20me0 occupancy 6 ( Supplementary Fig. 2a ) and recruitment of other HR factors 11, 19 . Importantly, mutation of the BARD1 ARD ablated recruitment of both BARD1 and BRCA1 to DSBs in the S phase ( Fig. 3a,b ). Of note, the BARD1 wild type and ARD mutants were expressed at similar levels across the cell cycle and were proficient for BRCA1 stabilization via the RING domain dimerization 3 ( Supplementary Fig. 2c,e ). Furthermore, we found that ARD recognition of H4K20me0 was as important as RNF8-dependent ubiquitination 14 for BRCA1 accumulation at DSBs ( Supplementary Fig. 3a ), indicating that BRCA1-BARD1 recruitment requires multivalent interactions with chromatin at DSBs, similar to 53BP1 (ref. 20 ). Our finding that H4K20me0 is essential for BRCA1-BARD1 recruitment explains why forced methylation of H4K20 by non-degradable SET8 blocks BRCA1 recruitment and RAD51 loading at DSBs in the S phase 12 . Collectively, this establishes H4K20me0 recognition as the critical mechanism underlying specific recruitment of BRCA1 to DSBs in the S phase, and assigns a primary function to the BARD1 ARD.
A key essential activity of BRCA1 is to oppose the anti-resection activity of 53BP1 (refs. 4, 5, 11, 12 ) to direct DSBs towards HR. 53BP1 accumulation at DSBs is dependent on recognition of H4K20me1/2 by its Tudor domain and RNF168-dependent mono-ubiquitination of histone H2A lysine 15 (ref. 14 ) . However, BRCA1 can prevent 53BP1 access to repair sites 11, 12 . We therefore hypothesized that BARD1 recognition of H4K20me0 might target BRCA1-BARD1dependent exclusion of 53BP1 to post-replicative chromatin. BRCA1 foci dominated in the mid and late S phase in the presence of the BARD1 wild type as expected 11 , but, remarkably, this pattern was reversed by the BARD1 ARD mutant ( Supplementary Fig. 3b ). The BARD1 ARD mutant also completely failed to suppress 53BP1 accumulation at DSBs in BARD1-depleted S-phase cells ( Fig. 3c,d ). This switch from BRCA1-BARD1 to 53BP1 dominance ablated DNA end resection ( Fig. 3e ) and RAD51 loading ( Fig. 3f ), indicating that BARD1 ARD mutant cells cannot route DSBs to HR.
These results show that BARD1 ARD recognition of H4K20me0 is required to recruit BRCA1 and curb 53BP1 anti-resection activity at DSBs in the S phase.
To address the implications for HR directly, we took advantage of a HR reporter carrying two differentially mutated green fluorescent protein (GFP) genes oriented as direct repeats (DR-GFP) 21 using both U-2 OS cells depleted for endogenous BARD1 and a BARD1-null mouse mammary carcinoma cell line 22 . Mutation of the ARD ablated BARD1 function in HR in both systems (Fig. 4a,b ). Consistent with a role of the H4K20me0 recognition in antagonizing 53BP1, depletion of 53BP1 partly restored HR in cells expressing the ARD mutant ( Supplementary Fig. 3c ). Moreover, mutation of the H4K20me0 recognition site was as detrimental to HR as deletion of the full ARD or BRCA1 carboxy (C) terminus (BRCT) domain previously shown to be essential for HR 22 (Fig. 4b and Supplementary Fig. 3d ), underscoring that the essential function of the ARD in HR is H4K20me0 recognition. In these experiments, we included mouse BARD1 as a control and found that it rescued HR activity ( Supplementary Fig. 3d ), although N470, predicted to bind H4K20me0 (Fig. 1b ), is not conserved in mice. This suggested that the H4K20me0 reader domains in BARD1 and TONSL differ with respect to some H4 tail interactions. Taking advantage of the high-resolution structures of the TONSL ARD-H3-H4 (ref. 6 ) complex and the BARD ARD 17 , we used the Rosetta modelling package to exhaustively model the structure of the BARD1 ARD-H3-H4 complex. The best-scoring structures predicted a repositioning of H4 R17, reducing the contacts between the H4 tail and BARD1 N470 as compared to N571 in TONSL ( Supplementary Fig. 4a,b ). All other interactions were highly similar between the two reader domains-in particular, the contacts between BARD1 E467 and D500 with H4 H18 and the contacts between BARD1 E429, D458 and E467 with H4K20 were conserved ( Supplementary Fig. 4a,b ). Consistent with this binding model, residues E467 and D500, but not N470, were critical for BARD1 chromatin binding and recruitment to ionizing irradiation-induced DSBs ( Supplementary Fig.  4c,d ). These key acidic residues diverge from the consensus ankyrin repeat 17 , but are conserved across species in BARD1, TONSL and SLF1 ( Supplementary Fig. 4e ), explaining the specialization of these ARDs for H4K20me0 recognition.
Many mutations in the BARD1 ARD have been identified in cancer, and our structural model pinpoints those with the potential to disrupt H4K20me0 binding and promote carcinogenesis by crippling HR (Fig. 4c ). HR deficiency is exploited in the treatment of tumours with BRCA1 and BRCA2 mutations 23 as it sensitizes tumour cells to the poly (ADP-ribose) polymerase inhibitors (PARPi). Defects in H4K20me0 recognition are therefore expected to sensitize cells to PARPi treatment. Consistent with this prediction, a functional H4K20me0 recognition interface was required for BARD1 to rescue sensitivity to PARPi in BARD1-depleted cells (Fig. 4d ). The BARD1 ARD mutant even impaired HR and sensitized cells to PARPi in a dominant negative manner ( Fig. 4e ,f), underscoring that H4K20me0 recognition is essential to BRCA1-BARD1 function in HR.
A role for the BARD1-BRCA1 E3 ubiquitin ligase activity in promoting HR was also recently reported and proposed to stimulate nucleosome remodelling events that inhibit 53BP1-dependent chromatin binding at DSB sites 24 . We therefore sought to determine the relative importance of H4K20me0 recognition in supporting BRCA1-BARD1-dependent HR over BARD1-dependent enzymatic E3 ubiquitin ligase activity. We generated a human conditional BARD1 knockout cell line by tagging both alleles of BARD1 with a C-terminal auxin-induced degron (AID) 25 , BARD1 AID/AID (Fig. 5a ), and then stably expressed BARD1 wild type or mutant transgenes. In BARD1 AID/AID HCT116 cells, doxycycline-induced expression of a OsTIR1 transgene, integrated in the adenoassociated virus integration site 1 (AAVS1) locus, allowed for efficient 
NATuRe Cell BIoloGy and stable depletion of endogenous BARD1 following the addition of auxin indole-3-acetic acid (IAA; Fig. 5a ). IAA-induced degradation of BARD1 resulted in BRCA1 destabilization ( Fig. 5a ) and PARPi hypersensitivity (Fig. 5b) . The destabilization of BRCA1 was equally bypassed in cells expressing wild-type and mutant BARD1 transgenes (Fig. 5c ). In addition to the recently reported BARD1 R99E RING domain mutant and BARD1 ARD 3A, we included a BARD1 BRCT-domain mutant (K619A) 26 that abrogates poly (ADP-ribose)dependent recruitment of BARD1 to stalled replication forks but is proficient for HR in mice 27 . In control (glutathione S-transferaseexpressing) BARD1 AID/AID cells, IAA treatment resulted in an acute hypersensitivity to PARPi (Fig. 5d ). This hypersensitivity was completely reversed by the expression of wild-type BARD1, or the BARD1 R99E and BARD1 K619A mutants (Fig. 5d ). In contrast, BARD1 ARD 3A expression failed to suppress PARPi sensitivity (Fig. 5d ).
These data indicate that ARD-mediated H4K20me0 binding represents a prime function for BARD1 in HR, while the E3-ligase activity and poly (ADP-ribose) binding are dispensable, consistent with these activities not being required for tumour suppression in mice 27, 28 . How cells switch from mutagenic NHEJ to error-free HR during S and G2 has been a long-standing question. Our results provide a simple solution in which ARD recognition of H4K20me0 triggers BRCA1-BARD1 recruitment specifically to post-replicative chromatin to antagonize 53BP1 and promote resection only when a sister chromatid is available for HR ( Fig. 5e ). This pre-lesion cisacting mechanism acts at the most upstream point in repair pathway choice before cell-cycle regulation of end resection 29 
NATuRe Cell BIoloGy of BRCA2 30 , as well as H4K20me0-mediated RAD51 loading via TONSL-MMS22L 6 . We propose that two complementary mechanisms control HR in mammalian cells-sister chromatid sensing via H4K20me0 (this work and ref. 6 ) and cell-cycle regulation 2 , which is well established at many levels. Consistent with this, HR is strongly impaired when the deposition of new histones and thus marking of post-replicative chromatin by H4K20me0 is attenuated 31 . Recognition of H4K20me0 on new histones by BARD1, contrary to recognition of H4K20me1/2 on old histones by 53BP1, explains the specific recruitment of BRCA1 to DSBs in S/G2, including the competition between pro-and anti-resection activities at lesions in S/G2 chromatin 32 where H4K20me0 and H4K20me1/2 marked nucleosomes coexist. At DNA break sites, H4K20 binding is integrated with additional signals, as both 53BP1 (ref. 20 ) and BRCA1-BARD1 (refs. [33] [34] [35] and this work) rely on multivalent binding for accumulation (including RNF8-and RNF168-dependent ubiquitination 14 ). This cross-talk between the pathways with respect to ubiquitin signalling remains enigmatic but suggests a constant competition for chromatin binding between 53BP1 and BRCA1-BARD1 that converges at DSBs and is tuned to the replicative state of a genomic locus by H4K20 methylation status. Competition for ubiquitin binding at DSBs may also explain the futile recruitment of BRCA1 to DSBs in G1 cells that lack 53BP1 (ref. 36 ). In the presence of 53BP1, recognition of H4K20me0 provides BRCA1-BARD1 with an advantage in post-replicative chromatin, tipping the balance towards 53BP1 exclusion and induction of HR, which is then executed by downstream cell-cycle-regulated factors. Our data argue that ARD recognition of H4K20me0 mediates an essential HR function of BARD1, providing molecular insight into the function of the highly conserved ARD, and identifying the enigmatic HR function of BARD1 beyond BRCA1 stabilization 37 . Our work explains how the availability of a sister chromatid substrate for HR directs repair pathway choice, and the druggability of histone reader domains 38 suggests that this mechanism can be exploited for targeting BRCA1 in cancers addicted to HR. Supplementary Fig. 5 for unprocessed blots) . Asterisks indicate non-specific bands. b, IAA addition hypersensitizes BARD1 AID/AID HCT116 cells to olaparib. Cells were seeded in the presence of doxycycline. IAA and olaparib were added 1 d later and left for 7 d before staining with crystal violet. Representatives of two biological replicates are shown. c,d, Analysis of BARD1 ARD function in PARPi resistance, as defined in BARD1 AID/ AID HCT116 cells. After 24 h in doxycycline, the indicated cell lines were treated with IAA or carrier (dimethyl sulfoxide (DMSO)) before immunoblotting whole-cell lysates (c) or measuring growth in the presence of olaparib (d), as indicated. In c, western blots show equal stabilization of endogenous BRCA1 by the expression of wild-type and all mutant BARD1 transgenes, but not the control (glutathione S-transferase (GST)) transgene. Representatives of two biological replicates are shown (see Supplementary Fig. 5 . for unprocessed blots). */eBARD1 indicates a weak unspecific band and the size of exogenous BARD1. In d, mean ± s.d. olaparib sensitivity was determined by resazurin cell viability assay 7 d following incubation with olaparib (a twofold dilution range from 7.8 nM-2 μM) in the presence (left) or absence of IAA (right) (n = 3 independent experiments). e, Schematic illustrating how BARD1 recognition of H4K20me0 licenses DSBs in sister chromatids for HR. BRCA1-BARD1 identifies post-replicative chromatin by recognition of H4K20me0 on new histones, thereby enabling the complex to oppose 53BP1 function when a sister chromatid can be used for homology-directed error-free repair of DSBs.
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Methods Preparation of recombinant histones. Recombinant human core histone proteins were expressed in Escherichia coli BL21(DE3)/RIL cells from pET21b(+) (Novagen) vectors, and purified by denaturing gel filtration and ion exchange chromatography, essentially as described 39 . Nucleosome assembly. Histone octamers were refolded from the purified histones and assembled into nucleosomes with biotinylated DNA via salt deposition dialysis as previously described 39 . Biotinylated nucleosomal DNAs containing two 601 nucleosome positioning sequences separated by a 50 base pair (bp) linker (di-nucleosomes) were prepared as described 39 . Di-nucleosomes were assembled in the presence of mouse mammary tumour virus A (MMTV A) competitor DNA and a slight excess of octamers to ensure saturation of the 601 repeats. The reconstituted di-nucleosomes were then immobilized on Streptavidin Sepharose High Performance beads (GE Healthcare) via the biotinylated DNA, washed to remove MMTV A competitor DNA and MMTV A nucleosomes, and directly used for stable isotope labeling with amino acids in cell culture (SILAC) nucleosome affinity purification (SNAP). Correct assembly and immobilization of nucleosomes was verified by native polyacrylamide gel electrophoresis.
Preparation of truncated histone
SNAP. SILAC-labelled nuclear extracts were prepared from HeLa S3 cells as previously described 39 Mass spectrometry. Samples were loaded at 8 μl min −1 onto a trap column (Thermo Fisher Scientific Acclaim PepMap 100; 100 μm internal diameter, 2 cm length, C18 reversed-phase material, 5 μm diameter beads and 100 Å pore size) in 2% acetonitrile and 0.1% trifluoroacetic acid.
Peptides were eluted on line to an analytical column (Thermo Fisher Scientific Acclaim PepMap RSLC; 75 μm internal diameter, 25 cm length, C18 reversed-phase material, 2 μm diameter beads and 100 Å pore size) and separated using a flow rate of 250 nl min −1 and gradient conditions of: initial 5 min with 4% buffer B, then 90 min gradient 4-25% B, then 30 min gradient 25-45% B, then 1 min gradient 45-90% B, and finally 15 min isocratic at 100% B before returning to starting conditions for a 15 min equilibration (buffer A: 2% acetonitrile and 0.1% formic acid in water; B: 80% acetonitrile and 0.1% formic acid).
The Q Exactive instrument acquired full-scan survey spectra (m/z 300-1,650) at 70,000 resolution. An automatic gain control target value of 3 × 10 6 and a maximum injection time of 20 ms were used. The top 10 most abundant multiply charged ions were selected in a data-dependent manner, fragmented by higherenergy collision-induced dissociation, and data were collected over the range 200-2,000 m/z at 17,500 resolution. An automatic gain control target value of 1 × 10 5 with a maximum injection time of 120 ms was used. A dynamic exclusion time of 30 s was enabled.
Mass spectrometry data processing. Protein abundances from the Q Exactive mass spectrometer were quantified by MaxQuant 1.6.0.16 using 2-plex labeling (Arg10 and Lys8). The search was run against human UP000005640 proteome (version GCA_000001405.26) from UniProt. Search parameters were set up to allow variable oxidation on methionines and acetylation on amino termini, as well as fixed carbamidomethylation on cysteines. Tryptic peptides with up to two missed cleavages were considered for analysis, and tolerance settings were set to Orbitrap instrument. Co-fragmented peptide identification and matching between runs was enabled. For protein quantification, the minimum ratio count was set to 1, and remaining settings were left as default. The normalized heavy/light (H/L) ratios in proteinGroups.txt file output by MaxQuant were transformed to a log 2 scale for further processing. Each protein in the dataset containing the ankyrin repeat-containing domain was identified using information from the InterPro superfamily IPR036770. Twenty-six proteins that were marked as either 'potential contaminant' , 'reverse' or 'only identified by site' by MaxQuant were dropped from the dataset (that is, 1.81% of the data). A further 76 proteins (5.39% of the remaining data) were dropped because they had only a forward or reverse ratio, but not complete pairs. The data presented in Fig. 1a are zoomed in to log 2 [fold change] ratios below the value of 5, thus excluding 4 outlier proteins (SPTA1, STAG2, histone H3 and histone H4) that are not enriched in either nucleosome pull-down. The full proteomics list for H4K20me0/me2 nucleosome pull-downs is presented in Supplementary Table 1 .
Di-nucleosome pull-down assay. Biotinylated di-nucleosomes carrying H4K20me0 or H4K20me2, or biotin only as a control, were mixed with MyOne T1 Streptavidin beads (Thermo Fisher Scientific) in Coupling Buffer (10 mM Tris-HCl, 1 mM EDTA and 250 mM KCl). Di-nucleosomes and beads were incubated for 1 h at 4 °C on a rotating shaker to allow the coupling and, subsequently, washed twice with SNAP buffer (20 mM HEPES, 150 mM NaCl, 0.2 mM EDTA, 10% glycerol and 0.1% NP-40). At the same time, 320-450 μg of HeLa cell nuclear extracts were incubated with 10 μg ml −1 Herring Sperm DNA (Sigma-Aldrich) in SNAP buffer (final volume: 900 μl) and allowed to rotate for 1 h at 4 °C. Inputs of 2% of the extracts were taken before diluting each sample with SNAP buffer. The extracts were then added to the washed di-nucleosome-coupled beads and incubated for 4 h, rotating at 4 °C. The beads were then washed with 4 × 900 μl Wash Buffer (20 mM HEPES, 500 mM NaCl, 0.2 mM EDTA, 10% glycerol and 0.25% NP-40, supplemented with 10 μg ml −1 Herring Sperm DNA) for 2 min at 4 °C. After the last wash, the beads were carefully dried and boiled in 20 μl 1× Laemmli sample buffer (LSB; 50 mM Tris-HCl pH 6.8, 100 mM DTT, 2% SDS, 8% glycerol, bromophenol blue). Pull-downs were visualized by western blotting after protein separation on a NuPAGE 4-12% Bis-Tris gradient gel (Thermo Fisher Scientific).
Cell culture, transfection and drug treatment. U-2 OS (a gift from J. Bartek), HeLa S3 (a gift from P. Nakatani) and HCT116 cells (a gift from I. Tomlinson) were grown in Dulbecco's modified Eagle's medium (Gibco) containing 10% foetal bovine serum (HyClone), 1% penicillin/streptomycin and drugs for selection. Cells inducible for Flag-HA-BARD1 wild-type and ARD mutants were generated in Flp-In T-REx U-2 OS cells (Invitrogen) by transfection of pcDNA5/ FRT/TO-Flag-HA-BARD1 plasmids with Lipofectamine 2000, according to the manufacturer's protocol, and selection with hygromycin (200 μg ml −1 ). All cell lines were authenticated by western blotting and/or immunofluorescence. All cell lines used in this study tested negative for Mycoplasma contamination. Expression of Flag-HA-BARD1 was induced by the addition of 1 μg ml −1 of tetracycline (TET) for 24-48 h. For transient expression of Flag-HA-BARD1, expression plasmids were introduced by transfection with Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol and cells harvested 24-48 h post-transfection. To establish a parental cell line expressing the E3 ubiquitin ligase OsTIR1, HCT116 male colorectal carcinoma cells were simultaneously transfected with a version pX330 (Addgene plasmid 42230) containing a locus-specific guide RNA targeting AAVS1 (5′-GGGGCCACTAGGGACAGGAT-3′) and pMK243 Tet-OsTIR1 (Addgene plasmid 72835) using FuGENE HD (Promega). Individual
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